Literature DB >> 17593626

MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer.

S Roy1, E Kenny, S Kennedy, A Larkin, J Ballot, M Perez De Villarreal, J Crown, L O'Driscoll.   

Abstract

BACKGROUND: Multiple drug resistance (MDR), both inherent and acquired, is a serious problem in non-small cell lung carcinomas (NSCLC). The purpose of this study was to investigate the prevalence of expression of genes encoding drug efflux pumps, MDR1 and MRP-1, at both the mRNA and protein levels, in this type of cancer.
MATERIALS AND METHODS: Tumour specimens (38 cases) were analysed using immunohistochemistry and, where possible (30 cases), also using reverse-transcriptase polymerase chain reaction.
RESULTS: The results from this analysis indicated that either, or both, drug efflux pumps were frequently expressed in NSCLC. Expression of mrp1 was found to be predominant over mdr1 at the mRNA level, while MDR1 P-gp was more frequently detected than MRP-1 protein. In some cases, proteins encoding pumps were detected without corresponding mRNAs--possibly due to differing sensitivities of the analysis techniques.
CONCLUSION: Future studies of mdr1 and mrp1 using increased-sensitivity qPCR techniques, in parallel with protein analysis, in larger cohorts of cases may help to elucidate the role of drug efflux pumps in NSCLC multiple drug resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17593626

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  16 in total

1.  Expression of multidrug resistance proteins in retinoblastoma.

Authors:  Swati Shukla; Arpna Srivastava; Sunil Kumar; Usha Singh; Sandeep Goswami; Bhavna Chawla; Mandeep Singh Bajaj; Seema Kashyap; Jasbir Kaur
Journal:  Int J Ophthalmol       Date:  2017-11-18       Impact factor: 1.779

2.  Regulatory role of human AP-endonuclease (APE1/Ref-1) in YB-1-mediated activation of the multidrug resistance gene MDR1.

Authors:  Ranajoy Chattopadhyay; Soumita Das; Amit K Maiti; Istvan Boldogh; Jingwu Xie; Tapas K Hazra; Kimitoshi Kohno; Sankar Mitra; Kishor K Bhakat
Journal:  Mol Cell Biol       Date:  2008-09-22       Impact factor: 4.272

Review 3.  Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?

Authors:  Francisco S Chung; Jayson S Santiago; Miguel Francisco M De Jesus; Camille V Trinidad; Melvin Floyd E See
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

4.  Galectin-3 rs4652 A>C polymorphism is associated with the risk of gastric carcinoma and P-glycoprotein expression level.

Authors:  Yi Shi; Xiandong Lin; Gang Chen; Jun Yan; Mingang Ying; Xiongwei Zheng
Journal:  Oncol Lett       Date:  2017-10-23       Impact factor: 2.967

5.  Modulation of P-gp expression by lapatinib.

Authors:  Gráinne Dunne; Laura Breen; Denis M Collins; Sandra Roche; Martin Clynes; Robert O'Connor
Journal:  Invest New Drugs       Date:  2010-07-06       Impact factor: 3.850

6.  PKCalpha-induced drug resistance in pancreatic cancer cells is associated with transforming growth factor-beta1.

Authors:  Ying Chen; Guanzhen Yu; Danghui Yu; Minghua Zhu
Journal:  J Exp Clin Cancer Res       Date:  2010-08-05

7.  Do iron chelators increase the antiproliferative effect of trichostatin A through a glucose-regulated protein 78 mediated mechanism?

Authors:  Veli Kilinc; Abdulkerim Bedir; Ali Okuyucu; Osman Salis; Hasan Alacam; Sedat Gulten
Journal:  Tumour Biol       Date:  2014-03-13

8.  Association of single nucleotide polymorphisms in the MVP gene with platinum resistance and survival in patients with epithelial ovarian cancer.

Authors:  Ya-Nan Zhao; Dong-Ning He; Ya-DI Wang; Jun-Jie Li; Min-Wen Ha
Journal:  Oncol Lett       Date:  2016-03-08       Impact factor: 2.967

9.  Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.

Authors:  Naomi Walsh; Annemarie Larkin; Susan Kennedy; Lisa Connolly; Jo Ballot; Wei Ooi; Giuseppe Gullo; John Crown; Martin Clynes; Lorraine O'Driscoll
Journal:  BMC Urol       Date:  2009-06-24       Impact factor: 2.264

10.  [Not Available].

Authors:  Jana Rolff; Cornelia Dorn; Johannes Merk; Iduna Fichtner
Journal:  J Oncol       Date:  2009-06-14       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.